Solid forms of pharmaceuticals: Polymorphs, salts and cocrystals

Control and selection of the properties of active pharmaceutical ingredients is a crucial part of the drug development process. One major part of this process is the selection of an appropriate solid form. This review will discuss three major types of crystalline solids, polymorphs, salts and cocrystals and processes used to develop and find these forms.

[1]  R. Bucci,et al.  Determination of diclofenac salts in pharmaceutical formulations , 1998 .

[2]  C. C. Seaton,et al.  Designing Acid/Acid Co-Crystals through the Application of Hammett Substituent Constants , 2010 .

[3]  J. Rantanen,et al.  Insight into Thermally Induced Phase Transformations of Erythromycin A Dihydrate , 2006 .

[4]  Margaret C. Etter,et al.  Hydrogen bonds as design elements in organic chemistry , 1991 .

[5]  S. Vasavanonda,et al.  ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[6]  A. Serajuddin,et al.  Preformulation study of a poorly water-soluble drug, alpha-pentyl-3-(2-quinolinylmethoxy)benzenemethanol: selection of the base for dosage form design. , 1986, Journal of pharmaceutical sciences.

[7]  Joel Bernstein,et al.  Polymorphism in Molecular Crystals , 2002 .

[8]  A. Matzger,et al.  Form IV of carbamazepine. , 2002, Journal of pharmaceutical sciences.

[9]  Abu T M Serajuddin,et al.  Effect of chloride ion on dissolution of different salt forms of haloperidol, a model basic drug. , 2005, Journal of pharmaceutical sciences.

[10]  P. L. Gould,et al.  Salt selection for basic drugs , 1986 .

[11]  Matthew L Peterson,et al.  Celecoxib:nicotinamide dissociation: using excipients to capture the cocrystal's potential. , 2007, Molecular pharmaceutics.

[12]  Ning Shan,et al.  The role of cocrystals in pharmaceutical science. , 2008, Drug discovery today.

[13]  Keith Chadwick,et al.  The utility of a ternary phase diagram in the discovery of new co-crystal forms , 2009 .

[14]  Ron J Roberts,et al.  Structure, solubility, screening, and synthesis of molecular salts. , 2007, Journal of pharmaceutical sciences.

[15]  W. Ritschel,et al.  Gastrointestinal parameters that influence oral medications. , 1993, Journal of pharmaceutical sciences.

[16]  Jeanette T. Dunlap,et al.  Crystal engineering approach to forming cocrystals of amine hydrochlorides with organic acids. Molecular complexes of fluoxetine hydrochloride with benzoic, succinic, and fumaric acids. , 2004, Journal of the American Chemical Society.

[17]  Jeanette T. Dunlap,et al.  A metastable polymorph of metformin hydrochloride: Isolation and characterization using capillary crystallization and thermal microscopy techniques , 2004 .

[18]  Alfred Y Lee,et al.  Concomitant Polymorphism in Confined Environment , 2008, Pharmaceutical Research.

[19]  Sekhar Surapaneni,et al.  The co-crystal approach to improve the exposure of a water-insoluble compound: AMG 517 sorbic acid co-crystal characterization and pharmacokinetics. , 2008, Journal of pharmaceutical sciences.

[20]  L. Szente,et al.  Cyclodextrin complexes of salts of acidic drugs. Thermodynamic properties, structural features, and pharmaceutical applications. , 2001, Journal of pharmaceutical sciences.

[21]  Donald C. Monkhouse,et al.  Review ArticlePharmaceutical Salts , 1977 .

[22]  R. Bandichhor,et al.  An Improved Process for Pioglitazone and Its Pharmaceutically Acceptable Salt , 2009 .

[23]  R. S. Hashim,et al.  Grid-based molecular modeling for pharmaceutical salt screening: Case example of 3,4,6,7,8,9-hexahydro-2H-pyrimido (1,2-a) pyrimidinium acetate. , 2006, Journal of pharmaceutical sciences.

[24]  Allan S. Myerson,et al.  Concomitant Crystallization of ROY on Patterned Substrates: Using a High Throughput Method to Improve the Chances of Crystallization of Different Polymorphs , 2009 .

[25]  Richard J. Bastin,et al.  Salt Selection and Optimisation Procedures for Pharmaceutical New Chemical Entities , 2000 .

[26]  Christer B Aakeröy,et al.  Cocrystal or salt: does it really matter? , 2007, Molecular pharmaceutics.

[27]  Michael Ouellette,et al.  An Approach to Early-Phase Salt Selection: Application to NBI-75043 , 2007 .

[28]  P. W. Cains,et al.  Sonocrystallization: The Use of Ultrasound for Improved Industrial Crystallization , 2005 .

[29]  Elies Molins,et al.  Effect of the Counterion on the Solubility of Isostructural Pharmaceutical Lamotrigine Salts , 2009 .

[30]  W R Porter,et al.  Physicochemical considerations in the preparation of amorphous ritonavir-poly(ethylene glycol) 8000 solid dispersions. , 2001, Journal of pharmaceutical sciences.

[31]  Michael J Cima,et al.  High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids. , 2004, Advanced drug delivery reviews.

[32]  William Jones,et al.  Pharmaceutical Cocrystallization: Engineering a Remedy for Caffeine Hydration , 2005 .

[33]  S. Byrn.  Solid state chemistry of drugs , 1982 .

[34]  J. Bauer,et al.  Ritonavir: An Extraordinary Example of Conformational Polymorphism , 2001, Pharmaceutical Research.

[35]  M. Hollingsworth,et al.  Unanticipated guest motion during a phase transition in a ferroelastic inclusion compound. , 2002, Journal of the American Chemical Society.

[36]  Jukka Rantanen,et al.  Solid form screening--a review. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[37]  Sarah J. Nehm,et al.  Phase solubility diagrams of cocrystals are explained by solubility product and solution complexation , 2006 .

[38]  Peddy Vishweshwar,et al.  Pharmaceutical co-crystals. , 2006, Journal of pharmaceutical sciences.

[39]  Michael J. Zaworotko,et al.  Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improved medicines? , 2004 .

[40]  C. A. Mitchell,et al.  Thermochemistry and Conformational Polymorphism of a Hexamorphic Crystal System , 2000 .

[41]  A. Myerson,et al.  Polarization switching of crystal structure in the nonphotochemical light-induced nucleation of supersaturated aqueous glycine solutions. , 2002, Physical review letters.

[42]  Orn Almarsson,et al.  Crystal engineering of novel cocrystals of a triazole drug with 1,4-dicarboxylic acids. , 2003, Journal of the American Chemical Society.

[43]  J. Wagner,et al.  pH-Related Changes in the Absorption of Dipyridamole in the Elderly , 2004, Pharmaceutical Research.

[44]  A. Newman,et al.  Pharmaceutical Cocrystals and Their Physicochemical Properties , 2009, Crystal growth & design.

[45]  M. Caira,et al.  Crystalline Polymorphism of Organic Compounds , 1998 .

[46]  I. Miroshnyk,et al.  Pharmaceutical co-crystals–an opportunity for drug product enhancement , 2009, Expert opinion on drug delivery.

[47]  G. Flynn,et al.  Solubility of organic hydrochlorides. , 1972, Journal of pharmaceutical sciences.

[48]  In Sung Lee,et al.  Crystallization on confined engineered surfaces: a method to control crystal size and generate different polymorphs. , 2005, Journal of the American Chemical Society.

[49]  I. Miroshnyk,et al.  Influence of solvents on the variety of crystalline forms of erythromycin , 2003, AAPS PharmSci.